There are no related discussions.
Novartis strikes licensing deal with Incyte
Article | 26 November 2009
The Swiss drug giant Novartis has secured a licensing deal with America’s Incyte Corp that gives it the rights to two potential treatments for a range of blood disorders and cancers. The lead compound covered by the deal is Incyte’s JAK inhibitor INCB18424, an oral therapy in phase 3 clinical trials for the treatment of myelofibrosis, a life-threatening bone marrow disease for which there is no effective cure. According to Novartis, the JAK inhibitor could become a “first-in-class therapeutic agent for the treatment of this and other hematologic diseases.”
Novartis will make an upfront payment of $150m for the JAK inhibitor, along with a first milestone payment of $60m following the recent initiation of European phase 3 trials for the drug. Each company will be responsible for costs in their respective territories but will share the expense of collaborative studies. Novartis will have commercialisation rights outside the US, while Incyte retains the rights in America and will be eligible for payments once further development and commercialisation milestones are reached. It also stands to gain royalties of over 10% on future sales.
Enjoying this article? Have the leading Biopharma news & analysis delivered daily on email by signing up for our FREE email newsletter here.
The other treatment in the licensing deal is a cMET inhibitor known as INCB28060, a cancer therapy still only entering phase 1 development , to which Novartis will have worldwide rights. Incyte has an option to co-promote the drug if it makes it onto the market and will receive royalties from any future sales. “This agreement leverages these two promising investigational drugs with Novartis Oncology’s global development and commercialisation expertise and our wide range of multi-targeted approaches to cancer treatment”, said David Epstein, president and CEO, Novartis oncology and Novartis Molecular Diagnostics.Novartis is certainly “an ideal partner” for Incyte given its “formidable experience in building a market in the hematology-oncology field”, said Cory Kasimov of JP Morgan, and it’s “impressive” that Incyte has managed to retain 100% of the US rights. The terms of the deal for Incyte “exceed expectations”; management has delivered a “high-quality” agreement. And a “lucrative” one, as Tom Russo of Robert W. Baird noted: Incyte could earn up to $1.3bn on this tie-up-- a sum equivalent to its current market capitalisation. Les Funtleyder of Miller Tabak was also impressed with the agreement on the JAK inhibitor: “this is a real endorsement for Incyte’s compound.”
The latest discussion & debate from thepharmaletter.com discussion forums...
Gas Generators V Gas Cylinders
Peak Scientific Instruments have been established as a pioneer in Gas Generation since 1973 we are known worldwide for our excellent product range of on site gas generation
Promoting 'Safety and Efficiency in the Laboratory Environment.
Peak Scientific Instruments have a mission - to replace all cylinders. As a manufacturer of laboratory nitrogen, hydrogen & zero air gas generators they want to make everyone aware of the dangers & inconveniences of combustible gas cylinders. A Peak gas generator offers the safer solution to your gas needs by eliminating cylinders in the lab. Stop yourself worrying about the safe handling of gases, the safety valves, the explosion risk, the storage, the re-ordering & all the other things that go along with being a cylinder user - replace your cylinders with a safe, economical, endless supply of gas from a Peak generator.
Call Maureen on 0141 530 4168 or visit www.peakscientific.com
2010-01-28 09:33:10
Here just we are itroducing ourself.Barat Bioinformatics Research Institute (BBRI) is consultancy and service provider in the field of Bioinformatics and Information Technology. We aim at delivering innovative and customized Insilico solutions matched to the special needs of biotechnological and pharmaceutical origin. And we can deliever at intime datamining works.
contact
nagireddy@bbri.in visit us at www.bbri.in
2009-12-14 05:41:17
Hi all,
Apologies for the product placement here, but we just wanted to introduce ourselves. We host a lot of pharmaceutical conferences and would love to host more! If you are looking for a venue for a meeting, conference or event, Nottingham Conferences offers four flexible venues with excellent facilities, do get in touch if you are interested.
Give us a call on 0115 846 8000, visit www.nottinghamconferences.co.uk, or e-mail us at conferences@nottingham.ac.uk.
Thanks again for your time.
Kirstie
2009-12-11 11:05:02
